Provectus Pharmaceuticals Inc. To Present At The Rodman & Renshaw Techvest 7th Annual Healthcare Conference
KNOXVILLE, Tenn., Nov. 7 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today announced today that it is scheduled to make an investor presentation at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at 12:20 p.m. ET on Wednesday, November 9, 2005. The conference is being held at the Palace Hotel in New York City November 7-9, 2005.
A live webcast of the Company's presentation will be available via a link provided at http://www.pvct.com. An archive of the presentation will begin shortly after the presentation time and will be available for 90 days. Web participants are encouraged to go to the Company's website at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl(TM), a treatment for psoriasis.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011. For more information, contact the Company at email@example.com or visit the corporate Web site: http://www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward-looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.Provectus Pharmaceuticals, Inc.
CONTACT: Investors: Matt Clawson of Allen & Caron Inc for ProvectusPharmaceuticals, Inc., +1-949-474-4300, firstname.lastname@example.org; PeterCulpepper of Provectus Pharmaceuticals Inc, +1-865-769-4011,email@example.com
Web site: http://www.pvct.com/